Genmab — Juli 2018
-
Grunden til at vi fik et positivt luk var, at Danske løb tør. De havde kun 1000 aktier tilbage i auktionen, efter at ha
ve holdt kursen nede hele dagen. Danske og ABG har dagen igennem netto solgt flere, end de anonyme har har netto købt, og de har næsten været ene om at købe. så - bibob (10.28) der var nogen, der ville sælge. -
Ser ud til at ADC terapierne er lidt i unåde. https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc?mkt_tok=eyJpIjoiWldRM05qUTVaVFk0WW1FMyIsInQiOiJoWXJOZTBhNzhjNWdlXC9sU3FWeTJVNFwvbVUyalc4YVpDWm1JS2FleFhXZlJWcVY2Tk5TN3VaeFo3ek9HOHFyQVIydjZ3RlM3U09JTWY4NDdsVDlFdlhNUjhJQmJvQ01TaTRmdElCYWdEUkwyUk1Fc1lsaXdMWlFPSklhK25xVUVQIn0%3D&mrkid=41140432
-
Limo Chen, CD38-mediated immunosuppression as a mechanism of tumor cell
escape from PD-1/PD-L1 blockade http://cancerdiscovery.aacrjournals.org/content/candisc/early/2018/07/14/2159-8290.CD-17-1033.full.pdf -
The mechanism of immune resistance to anti-PD- L1/PD-1 therapy caused by CD38 provides an evident rationale for recruitment of cancer patients for clinical trials of anti-CD38 in combination with anti-PD-L1/PD-1 to prevent therapy resistance and further enhance anti-tumor efficacy.
-
CD38 as a novel immune checkpoint and a mechanism of resistance to the blockade of the PD-1/PD-L1 axis.
L Chen, LA Byers, S Ullrich, II Wistuba, XF Qin… - 2017 - ascopubs.org -
Targeting CD38 to improve anti-PD-1/CTLA-4 combination therapy in lung cancer.
L Chen, Y Li, X Yi, DL Gibbons - 2018 - ascopubs.org -
Fra nummer fire hedder det: "Overall the therapeutic studies demonstrate that combination CD38 and PD-L1 blockade substantially reduces primary tumor burden and
metastases, that CD38 can be used in combination or in a sequential manner upon the
acquisition of resistance, and that targeting CD38 or the downstream adenosine
signaling is highly effective. -
To model how CD38-blocking strategies might be translated into the clinic for patients
with disease refractory to anti-PD-1/PD-L1, we tested sequential treatment after the
development of resistance to anti-PD-L1 by treating animals with anti-CD38 antibody
alone.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind